GSK spotlights oral care; Mead Johnson weighs China pricing effects; USANA builds on Asia enthusiasm; FMC lands omega-3 firm Epax; Actavis eyes additional M&A activity; ScripsAmerica grows OTC and Rx distribution.

GSK spotlights oral care; Mead Johnson weighs China pricing effects; USANA builds on Asia enthusiasm; FMC lands omega-3 firm Epax; Actavis eyes additional M&A activity; ScripsAmerica grows OTC and Rx distribution.

Noscira's novel Alzheimer's disease-modifying oral drug candidate Nypta (tideglusib; NP-12) has achieved positive results in a Phase IIa study presented at the recent International Conference on Alzheimer's disease (ICAD) in Hawaii.

Yondelis (trabectedin) again drove the Spanish biotech group Zeltia's first-quarter business and helped the group's EBITDA break even.